• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 8th April 2019

The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment

A new OHE Research Paper reviews a recent report on cancer pricing published by the World Health Organization. The authors argue that the report fails to promote mechanisms that are key to efficient pricing and use of cancer medicines. The…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

A new OHE Research Paper reviews a recent report on cancer pricing published by the World Health Organization. The authors argue that the report fails to promote mechanisms that are key to efficient pricing and use of cancer medicines. The Research Paper outlines some for addressing these shortcomings.

A new OHE Research Paper by Simon Brassel, Olga Rozanova, and Adrian Towse reviews a recent report on cancer pricing published by the World Health Organization (WHO). The authors argue that the report fails to promote mechanisms (value assessment and related pricing arrangements) that are key to efficient pricing and use of cancer medicines. This is a missed opportunity. WHO should also support differential pricing of on-patent drugs and vaccines, which is crucial to increasing access. It should oppose the Report’s advocacy of transparency of on-patent pricing, which will reduce access to medicines.

At the end of 2018 a WHO Technical Report was published in order to address requests made in a resolution adopted by the 2018 Seventieth World Health Assembly (WHA) on Cancer prevention and control in the context of an integrated approach.

The report dismisses value assessment and the fundamental role of value assessment in delivering value for money. This is inconsistent with both existing WHA policy on Health Technology Assessment (HTA) and the reality that more and more payers in WHO Member States are using value assessment analyses to support their purchasing decisions. The report also lacks proposals to enable differential pricing and managed entry agreements to happen. Both can increase access while setting the right incentives for future innovation if implemented correctly. The report calls for price transparency and price caps which are likely to have a negative impact on differential pricing and managed entry agreements, reducing access to treatment for patients and producing less innovation in the future.

Much of the emphasis of the report is that the R&D ‘supply side’ is not working as the authors would like, but we are not convinced that this is the major challenge. Supply responds to demand and the real challenge is to get demand side reforms that use new treatments efficiently and send the right signals to industry about the new cancer treatments (and associated health gains) that payers want to fund.

The Report fails to promote mechanisms and processes (value assessment and related pricing and purchasing arrangements) that are key to efficient pricing and use of cancer medicines. This is a missed opportunity. In our view, the priorities for WHO should be to:

  1. Provide support for Member States introducing effective HTA and related priority setting mechanisms in order to support both the introduction of universal health care and more efficient pricing and reimbursement mechanisms based on value-based pricing.
  2. Ensure HTA reflects the context both in terms of the elements of value deemed relevant and in the impact on the healthcare system. There may be important differences between high-income and low- and middle-income countries as to the character of HTA.
  3. Advocate differential pricing of drugs and vaccines. This is crucial to increasing access to on-patent products.
  4. Oppose transparency of on-patent pricing. This will reduce both access to medicines and R&D.
  5. Recognise that most products that underpin health care provision (by value and volume in low- and middle-income countries and by volume in high-income countries) are off-patent multi-source generics (and, in the future biosimilars). Advice on the effective procurement of these products is key.
  6. Acknowledge that R&D is best incentivised by use of value-based assessment of health and health-related outcomes and by value-based pricing. Additional incentives may be needed for ultra-orphan drugs in oncology and other diseases. Effective management of the demand side of the health system is a far more effective way to get R&D that meets patient and health system needs than seeking to restructure R&D.

This study was commissioned and funded by the International Federation of Pharmaceutical Manufacturers (IFPMA).

Citation

Brassel, S., Rozanova, O., and Towse, A., 2019. The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for HTA and Value Assessment. OHE Research Paper, London: Office of Health Economics.

Related research

Berdud, M., Chalkidou, K., Dean, E., Ferraro, J., Garrison, L., Nemzoff, C. and Towse, A., 2019. The Future of Global Health Procurement: Issues around Pricing Transparency. Office of Health Economics. RePEc.

  • Emerging Markets
  • Value, Affordability, and…
  • Pricing and Reimbursement

Related News

  • News
  • December 2020

Should We ‘Drop Dead’ from Health State Valuation?

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • June 2020

The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!